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S U M M A R Y
Background: Prospective studies from developing countries that have investigated risk factors for
trimethoprim–sulfamethoxazole (TMP–SMX)-resistant Escherichia coli in women with uncomplicated
urinary tract infection (UTI) remain scarce.
Methods: Women with acute uncomplicated UTI were enrolled prospectively. Urine was sent for
antimicrobial susceptibility testing. Logistic regression analysis was used to identify risk factors for
TMP–SMX resistance.
Results: Of 405 participants, 229 (56.5%) had bacteriuria (mean age 31.9  9.5 years). In the previous
12 months, 77 (33.6%) had experienced at least one UTI episode and 106 (46.3%) reported antimicrobial use.
The most common uropathogens were E. coli (75.8%) and Staphylococcus saprophyticus (8.9%). For the 179 E.
coli, resistance rates were highest for ampicillin (64.3%) and TMP–SMX (41.3%). Resistance to cephalosporins,
nitrofurantoin, and ﬂuoroquinolones was much lower compared with the hospital laboratory-based
surveillance data. Risk factors for TMP–SMX resistance were UTI in the last 6 months (odds ratio 2.22;
p = 0.04) and the number of UTI episodes in the past year (odds ratio 2.06; p = 0.004). The number of UTI
episodes (adjusted odds ratio 2.21; p = 0.02) remained signiﬁcant on multivariate analysis.
Conclusions: TMP–SMX resistance was high. Number of previous UTI episodes was associated with
increased risk of resistance; prior antimicrobial use was not. Hospital antibiograms should be used with
caution when treating uncomplicated UTI.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Urinary tract infection (UTI) remains one of the most common
clinical entities necessitating antimicrobial therapy. The emer-
gence and spread of drug-resistant uropathogens, particularly
Escherichia coli, even among community-acquired UTI, has limited
treatment choices.1–3 This is of particular concern in developing
countries where the capacity for resistance surveillance and access* Corresponding author, present address: Department of Internal Medicine,
Bridgeport Hospital, Yale New Haven Health, 267 Grant St., Bridgeport, CT 06610,
USA. Tel.: +632 706 2162.
E-mail address: louiemarMD@gmail.com (L.M. Gangcuangco).
http://dx.doi.org/10.1016/j.ijid.2015.02.022
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to healthcare are limited and over-the-counter drug purchase is
rampant in the community.4–6
International surveillance reports of increasing resistance
rates of community-acquired E. coli to trimethoprim–sulfa-
methoxazole (TMP–SMX), ﬂuoroquinolones (FQs), and other
frequently used drugs for the treatment of UTI are mostly
derived from the laboratory- and hospital-based collection
of urinary isolates.7–9 The degree to which these rates
reﬂect prevalence in the community is unknown. Additionally,
reported risk factors for resistance among truly community-
acquired uropathogens are limited to settings in the developed
world.10–16 The dearth of such information, particularly from
Asian developing countries, is alarming in light of the emergence
of highly drug-resistant community-associated strains in the
region.4,5,17ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Pathogens in acute uncomplicated urinary tract infectiona
Number
(n = 235)
Percent (%)
Pathogen
Gram-negative
Escherichia coli 179 76.2
Klebsiella pneumoniae 8 3.4
Enterobacter aerogenes 4 1.7
Citrobacter 3 1.3
Proteus mirabilis 3 1.3
Edwardsiella tarda 1 0.4
Gram-positive
Staphylococcus saprophyticus 21 8.9
Staphylococcus aureus 7 3.0
Streptococcus agalactiae 3 1.3
Staphylococcus hominis 2 0.9
Enterococcus faecalis 2 0.9
Staphylococcus haemolyticus 1 0.4
Staphylococcus warneri 1 0.4
a Six patients had mixed infections: S. hominis and S. saprophyticus; K.
pneumoniae and E. faecalis; E. coli and S. saprophyticus; S. saprophyticus and S.
aureus; E. coli and K. pneumoniae; and E. faecalis and S. aureus.
L.M. Gangcuangco et al. / International Journal of Infectious Diseases 34 (2015) 55–6056This study was conducted to prospectively determine the
resistance rates of E. coli isolated from women with uncomplicated
UTI in the Philippines and to compare these with data from parallel
laboratory-based surveillance. It was further aimed to identify
speciﬁc risk factors as independent predictors for resistance to
TMP–SMX and other antimicrobials among this population.
2. Methods
2.1. Study site and participants
The Medical City is a 600-bed private, tertiary care teaching
hospital in urban Metro Manila, with an estimated catchment
population of more than two million. Each year approximately
37 600 patients are admitted to the hospital and more than
100 000 outpatient visits are recorded. UTI is among the 10 leading
reasons for ambulatory consultation and hospital admission. The
majority of adult patients are middle to upper class professionals
and their family members, who use third party payer schemes
through health maintenance organizations, or have private or
government health insurance.
Women aged 18 years presenting to the emergency depart-
ment or outpatient clinics or admitted to the hospital with dysuria,
frequency, or urgency of less than 7 days duration, with or without
fever and ﬂank pain, were enrolled prospectively from July 2010 to
October 2011. Exclusion criteria were pregnancy, diabetes, known
anatomical or functional urologic abnormalities, urinary tract
instrumentation, and immunosuppression. Patients were included
only once in the study. All participants provided written informed
consent and the hospital ethics committee approved the study (IRB
Registry No. GCS IM 2010-030). The study was conducted in
accordance with the Declaration of Helsinki and patient conﬁ-
dentiality was ensured.
Patients were interviewed at enrolment using a standardized
form. Demographic and clinical data were collected, including
potential risk factors for drug resistance such as a history of any
antimicrobial use (excluding use for incident UTI), prior episodes of
UTI, hospitalization within the past year, and use of contraception.
Treatment decisions were left to the discretion of the attending
physician who had access to the laboratory data.
2.2. Microbiological examinations
Midstream, clean-catch urine samples were sent to the
laboratory for standard urinalysis and culture. Bacterial growth
of 104 CFU/ml urine was considered positive. Susceptibility
testing was performed using the Vitek 2 system (bioMe´rieux).
Minimum inhibitory concentration (MIC) breakpoints and quality
control protocols were based on the Clinical and Laboratory
Standards Institute (CLSI) recommendations.18 Intermediate and
resistant strains were categorized together as resistant. Less than
1% of the resistant strains demonstrated intermediate susceptibil-
ity. Extended-spectrum b-lactamase (ESBL) strains were detected
phenotypically in accordance with the CSLI recommendations.
The hospital’s continuous surveillance program monitors and
reports rates of resistance of various sentinel pathogens among
which are urine E. coli. Surveillance data on resistance rates of urine
E. coli isolates from ambulatory patients during the study period
were compared with E. coli resistance rates in the isolates from
women enrolled in the study.
2.3. Statistical analyses
Data were analysed using Stata Statistical Software, version
12.0 (StataCorp., College Station, TX, USA). Descriptive statistics
were used to summarize patient characteristics and the prevalenceof antimicrobial resistance. Univariate and multivariate analyses
for putative risk factors for TMP–SMX-resistant E. coli were
conducted. Variables with p < 0.10 on univariate analysis were
included in the multivariate analysis. The level of signiﬁcance was
set at p < 0.05, using two-sided comparisons. Risk factors included
age, history or presence of fever and hospitalization for incident
UTI, prior antimicrobial use within 3 and 12 months (excluding use
for the incident UTI), and history and number of UTI episodes in the
past 6 and 12 months.
3. Results
Of 405 patients enrolled, 229 (56.5%) had growth on urine
culture (104 CFU/ml). Only 11 (4.8%) of them had taken an
antimicrobial for the incident UTI prior to consultation compared
to 28 (15.9%) of those who had no growth on urine culture.
The mean age of the 229 patients with positive urine cultures
was 31.9  9.5 years. Twenty (8.7%) were hospitalized for the
incident UTI and 68 (29.7%) were febrile or had a history of fever.
Seventy-seven (33.6%) had experienced a UTI in the previous
12 months; 33 (42.8%) of these UTI episodes occurred within
3 months prior to consultation and 15 (19.5%) within 3 to 6 months
prior to consultation. Fifteen patients (5%) had experienced more than
one UTI episode in the past year; only ﬁve had had at least three
preceding UTI episodes. Almost half (106, 46.3%) reported antimicro-
bial use in the past year; 51 (22.3%) had taken an antimicrobial for
prior UTI. Antimicrobials previously taken were predominantly b-
lactams (38.2%), followed by FQs (19.5%) and TMP–SMX (6.3%); 26.6%
could not recall the speciﬁc antimicrobial class. Data regarding the
time elapsed between prior antimicrobial use for any indication and
the incident UTI episode were available for 83 of the 106 patients; 43
(18.8%) reported intake in the preceding 3 months. The duration of
antimicrobial use could not be obtained. A history of prior
hospitalization in the previous year was practically nil. Of the
229 patients, 28 (12.2%) had used an oral contraceptive; no patients
had used spermicides or intrauterine devices.
Of 229 patients with growth on culture, six had mixed
pathogens. The most common organisms isolated were E. coli
(76.2%), Staphylococcus saprophyticus (8.9%), and Klebsiella pneu-
moniae (3.4%) (Table 1). Four samples (2%) with 10 000 CFU/ml of
coagulase-negative staphylococci as pure growth (n = 3) or mixed
with S. saprophyticus (n = 1), with signiﬁcant pyuria (>5/high-
power ﬁeld), were considered to have true pathogens. The
Figure 1. Rates of resistance in urinary Escherichia coli from the current study (black columns, n = 179) compared with urine isolates from the outpatient hospital surveillance
system (grey columns, n = 700) during the same period.
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hospitalized patients, and between those with and without fever.
As shown in Figure 1, the resistance rates of the 179 E. coli
isolates were highest for ampicillin (64.2%), TMP–SMX (41.3%), and
amoxicillin–clavulanic acid (11.7%). Broad-spectrum cephalospor-
ins, gentamicin, levoﬂoxacin, and nitrofurantoin remained highly
active. Resistance to carbapenems was nil. Only three E. coli
isolates (1.7%) were ESBL-producing; none of the remaining
Enterobacteriaceae isolates were ESBL-positive. In contrast, the
hospital’s laboratory-based surveillance report on urine E. coli
isolated from outpatients during the study period (Figure 1)
showed much higher resistance rates not only for ampicillin
(74.3%), TMP–SMX (53.4%), and amoxicillin–clavulanic acid
(29.2%), but also for levoﬂoxacin (20.9%), gentamicin (17.0%),
and the cephalosporins (11.6–29.2%). Compared with TMP–SMX-
susceptible E. coli strains, TMP–SMX-resistant strains in this study
were signiﬁcantly more resistant to gentamicin, ampicillin, and
FQs (Table 2).
Risk factors for TMP–SMX-resistant E. coli on univariate analysis
are shown in Table 3. The number of prior UTI episodes in the
previous year (odds ratio (OR) 2.06, 95% conﬁdence interval (CI)
1.26–3.38) and the presence of UTI in the past 6 months (OR 2.22,
95% CI 1.05–4.70) were signiﬁcant. In the ﬁnal multivariate
analysis adjusted for age and the presence of UTI within 6 months
prior to consultation, only the number of UTI episodes in the
previous year (adjusted OR 2.21, 95% CI 1.11–4.37) was found to be
an independent risk factor (Table 4). Potential interactions (e.g.,
history of antimicrobial use and prior UTI) were tested, but theseTable 2
Susceptibility of Escherichia coli isolates to alternative antimicrobials stratiﬁed by
trimethoprim–sulfamethoxazole (TMP–SMX) susceptibility
No. (%) of isolates susceptible to an alternative
agent
Antimicrobial agent TMP–SMX-
susceptible
(n = 105)
TMP–SMX-
resistant
(n = 74)
p-valuea
Fluoroquinoloneb 102 (97.1) 66 (89.2) 0.03
Gentamicin 103 (98.1) 64 (86.5) 0.002
Ampicillin 61 (58.1) 3 (4.1) <0.001
Amoxicillin–clavulanic
acid
96 (91.4) 62 (83.8) 0.12
Cefazolin 100 (95.2) 67 (90.5) 0.22
Cefuroxime 102 (97.1) 70 (94.6) 0.39
Nitrofurantoin 98 (93.3) 67 (90.5) 0.37
a Fisher’s exact.
b Combined levoﬂoxacin (n = 175) and ciproﬂoxacin (n = 4).did not alter the results. In women without prior UTI, TMP–SMX
resistance remained high (34.2%). Prior antimicrobial exposure
(regardless of the indication, time interval before the episode, and
antimicrobial class) was not found to be a signiﬁcant factor.
4. Discussion
To our knowledge, this is the ﬁrst prospective study on the
prevalence and risk factors for antimicrobial resistance of
uropathogens among otherwise healthy women with communi-
ty-acquired uncomplicated UTI in a developing country setting.
Two other prospective studies from developing countries enrolled
adult outpatients with community-acquired UTI, but included
both men and women with uncomplicated and complicated
infections.19,20 Thus, their ﬁndings, which as expected showed
much higher rates of antimicrobial resistance, may not be
comparable to ours.
This study highlights the value of prospectively collected data
from a clearly deﬁned target population (i.e., previously healthy
women with acute uncomplicated UTI) in determining the true
burden of resistant E. coli in the local community. As shown in this
report, laboratory-based passive surveillance, even of outpatient
urine samples from patients in the same geographic area,
overestimates the prevalence of resistance, since patients with
complicated UTI and resistant strains are likely to be over-
represented.1,2,21–24
Unbiased surveillance of pathogens is important for antimicro-
bial decision-making. Unfortunately, such a database is non-
existent in the Philippines, as in most developing countries. The
national antimicrobial resistance program report for the same
period during which the study was conducted25 (based on passive
surveillance involving tertiary hospitals in Metro Manila and other
regions) showed high resistance rates of urine E. coli from
outpatients to commonly used agents such as ampicillin (82%),
TMP–SMX (66%), ciproﬂoxacin (49%), cefuroxime (39%), amoxicil-
lin–clavulanic acid (27%), and nitrofurantoin (12%); about 20%
were ESBL-producing. Reliance on such data and local hospital
antibiograms leaves limited choices for the empirical outpatient
treatment of uncomplicated UTI and may encourage the inappro-
priate use of more expensive broader-spectrum agents.
In the present study, high resistance of E. coli to ampicillin and
TMP–SMX was conﬁrmed. TMP–SMX resistance has long been
reported in developing countries2,19,20,26–33 and increasingly in the
developed world.1,7,9,34 In contrast, resistance to FQs and
cephalosporins was lower than expected in our study. However,
high rates of FQ resistance are being reported in the Asia-Paciﬁc
Table 3
Univariate analysis of factors associated with trimethoprim–sulfamethoxazole-resistant Escherichia coli
Risk factor TMP–SMX-susceptible
(n = 105)
TMP–SMX-resistant
(n = 74)
OR 95% CI p-value
Mean age, years 31.0 (SD 8.6), range 19–59 33.5 (SD 11.3), range 20–71 1.03 0.99–1.06 0.09
Mean number UTI episodes/year 0.3 (SD 0.52), range 0–2 0.76 (SD 1.55), range 0–12 2.06 1.26–3.38 0.004
Previous UTI within 6 months before consultation 15 (14.3%) 20 (27.0%) 2.22 1.05–4.70 0.04
With antimicrobial exposure in the past year 46 (43.8%) 39 (52.7%) 1.43 0.79–2.60 0.23
With antimicrobial use for previous UTI 23 (21.9%) 21 (28.4%) 1.41 0.71–2.80 0.32
With history of quinolone use for UTI 17 (16.9%) 6 (8.1%) 0.46 0.17–1.22 0.12
With TMP–SMX exposure 2 (1.9%) 4 (5.4%) 2.94 0.52–16.50 0.22
TMP–SMX, trimethoprim–sulfamethoxazole; OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; UTI, urinary tract infection.
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globally even for community-acquired infections.1,7,38–40
Aside from varying methodologies, geographic differences in
antimicrobial resistance likely reﬂect local patterns of antimicro-
bial use. Our patients were educated healthy adult women in an
urban community. The availability of medical insurance/third
party reimbursement possibly encouraged early consultation
instead of self-initiated treatment. Thus, <10% had taken any
antimicrobial for urinary symptoms prior to consultation. It should
be noted, however, that over-the-counter purchase of antimicro-
bials remains prevalent in other areas of the Philippines.6 Not
surprisingly, almost half of the women had taken an antimicrobial
in the previous year. FQs were preferred to TMP–SMX, reﬂecting
previously reported prescribing practices of private physicians in
the locality.41
Among the potential risk factors assessed for TMP–SMX
resistance, only the number of UTI episodes in the previous year
was shown to be a signiﬁcant predictor. Prior antimicrobial use
(which has classically been linked to resistance), regardless of class
and time elapsed before the incident episode, did not predict
resistance. This lack of association was unexpected and difﬁcult to
reconcile with the ﬁnding of the number of past UTI episodes (which
would likely trigger antimicrobial intake) as a risk factor. Failure to
ﬁnd an association could be due to a type II error, i.e., the association
could be in a range below what our study was able to detect. Data on
time elapsed were not available for 17% of those who had claimed
past antimicrobial exposure, thus decreasing the sample available
for risk assessment. Moreover, we had to rely on individual recall of
antimicrobial usage and could not quantify the degree of exposure
in terms of regimen duration and dosage. Thus, we could have
missed identifying any possible link between individual antimicro-
bial exposure and resistance. In a systematic review of the effect of
antimicrobial prescribing in primary care on drug resistance in
individual patients, a dose–response relationship, particularly for
trimethoprim and amoxicillin, was observed.42 Prior to this meta-
analysis, several studies that attempted to assess the relationship
between antimicrobial consumption and E. coli resistance showed
conﬂicting results.11,43–47Table 4
Multivariate analysis of factors associated with trimethoprim–sulfamethoxazole-
resistant Escherichia coli
Adjusted OR p-value 95% CI
Lower limit Upper limit
Age 1.03 0.09 1.00 1.06
Number of UTI
episodes in
the past year
2.21 0.02 1.11 4.37
Presence of UTI
within 6 months
prior to consult
0.88 0.82 0.30 2.59
OR: odds ratio; CI, conﬁdence interval; UTI, urinary tract infection.We found only two prospective studies in the Asia-Paciﬁc
region that have investigated risk factors for resistance among
women with acute uncomplicated UTI. These were conducted in
South Korea and Hong Kong, both developed country settings.15,48
Having two recurrences of UTI in the past year among Korean
women was predictive of E. coli resistance to ciproﬂoxacin and
cefazolin, but not to TMP–SMX.15 Among women in Hong Kong
with acute uncomplicated cystitis, recent antibiotic exposure was
associated with TMP–SMX- and ciproﬂoxacin-resistant E. coli.48 It
should be noted, however, that the population in the Hong Kong
study was older (mean age 44.9 years) and 11% had underlying co-
morbidities.
In other developed countries, studies that have attempted to
identify factors predicting TMP–SMX resistance have mostly been
retrospective, have included mixed gender and age groups, or
enrolled complicated UTI and hospitalized
patients.10,12,14,16,46,47,49 Some of the risk factors identiﬁed were
prior antimicrobial use, past UTI episodes or recurrent UTI,
oestrogen exposure, recent hospitalization or exposure to health
care settings, travel to areas with high rates of TMP–SMX
resistance, and exposure to children in day-care or to a household
member with recent antimicrobial use.
A prospective study of risk factors for TMP–SMX resistance that
strictly enrolled non-pregnant women with uncomplicated UTI
(acute cystitis) was done in an urban primary care practice setting
in the USA.13 As in our study, the use of TMP–SMX or any
antimicrobial in the previous 3 months was not associated with
resistance; however, the presence or number of UTI episodes in the
previous year was also not a risk factor, in contrast to our ﬁndings.
Interestingly, Asian race and recent travel were independently
associated with resistance. TMP–SMX-resistant isolates were more
likely to belong to clonal group A, an epidemic clone that is globally
distributed, with a strong collinearity with the Asian race. Another
prospective USA-based study found recent foreign travel and a
prior UTI episode, but not antimicrobial use, as risk factors for
TMP–SMX-resistant E. coli.12 As in our study, high rates of
resistance (>15%) were seen even among women without risk
factors.
How generalizable are our ﬁndings? In increasingly urbanized
developing countries with rising incomes and ready access to
healthcare, comparable antimicrobial resistance patterns may be
observed in community pathogens causing acute uncomplicated
UTI. Unfortunately, this remains conjectural because similar
prospective studies from other developing countries have yet to
be reported. Several other factors such as non-human antimicro-
bial usage, the availability of substandard drugs, a lack of
antimicrobial stewardship, poor sanitation and unsafe water
supplies, and other environmental inﬂuences would need to be
considered to determine the applicability of our ﬁndings to
developing countries in the region. Knowledge of the burden and
determinants of antimicrobial resistance is critical in Southeast
Asia where 48% of the population of 580 million people reside in
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infectious diseases as a result of population growth, urbanization,
environmental changes, and frail public health systems.4,5,50
This study has a number of limitations. First, data on the time
elapsed between prior antimicrobial use and the incident episode
of UTI were available for only 83% of women; antimicrobial class
was available, but the duration of use and dosage were self-
reported and could not be obtained reliably. Second, we did not
systematically collect data on possible indirect exposures, such as
history of hospitalization or antimicrobial use in a family member,
contact with pets and livestock, having a child in day-care (an
uncommon practice in the study area), and dietary habits. Third,
the sample size for multivariate risk factor analysis may have been
underpowered to determine additional signiﬁcant predictors of
resistance. Fourth, the study patients came from only one large
urban area. A more diverse geographic range of study participants
from both urban and rural settings, with varied health-seeking
behaviours and access to healthcare would have given a more
representative proﬁle. This is relevant since studies on E. coli in
developing countries have shown differences in faecal carriage of
resistant organisms between urban and rural settings.4
Our ﬁndings support the recommendation for the use of
nitrofurantoin, and not TMP–SMX, as the ﬁrst-line empiric
treatment for acute uncomplicated UTI among women in urban
communities in the Philippines. Based on the low resistance
proﬁle, oral ﬁrst- and second-generation cephalosporins also
appear to be acceptable. Unfortunately such antimicrobial choices
are more costly than TMP–SMX. FQs are recommended only as
alternative agents because of their propensity for collateral
damage, despite low resistance rates.1 This is particularly
important in areas where multidrug-resistant tuberculosis, the
treatment for which includes a FQ, has emerged as a public health
problem.51 Our ﬁndings need to be conﬁrmed by larger studies in
more diverse settings and replicated in other developing countries.
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